Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 9/20 | 0.50 |
| ▸ | HTR1A | P08908 | 8/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25301724 | 0.86 | HTR7 (0.49) | HTR7HTR1ADDB1CRBNADAMTS5 | |
| SCHEMBL25034750 | 0.85 | HTR7 (0.44) | HTR7HTR1ADDB1CRBNADAMTS5 | |
| SCHEMBL25033930 | 0.85 | HTR7 (0.42) | HTR7HTR1ADDB1CRBNADAMTS5 | |
| SCHEMBL30475475 | 0.85 | HTR7 (0.44) | HTR7HTR1ADDB1CRBNADAMTS5 | |
| SCHEMBL25031287 | 0.84 | HTR7 (0.46) | HTR7HTR1ADDB1CRBNADAMTS5 | |
| SCHEMBL29179852 | 0.82 | DDB1 (0.57) | HTR7HTR1ADDB1CRBNADAMTS5 | |
| SCHEMBL22119568 | 0.81 | CRBN (0.64) | DDB1CRBNALDH1A1 | |
| SCHEMBL25818079 | 0.81 | DDB1 (0.50) | HTR7HTR1ADDB1CRBNALDH1A1 | |
| SCHEMBL25035205 | 0.80 | KCNA3 (0.44) | HTR7HTR1ADDB1CRBN | |
| SCHEMBL29179871 | 0.80 | CRBN (0.52) | HTR7HTR1ADDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018238-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | HTR7 4012/4885HTR1A 4156/4885DDB1 132/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | HTR7 2918/4885HTR1A 2866/4885DDB1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.